Ozempic shortages and safety claims: what Irish TikTok gets right and wrong

What's this video probably claiming?

Based on the caption and hashtag context, this video appears to be doing a few things at once. It's positioning a hospital-affiliated expert as a credible endorser of semaglutide's safety profile, referencing RTE coverage to add journalistic legitimacy, and framing the Ozempic shortage in Ireland as a crisis that's leaving obesity patients without access to treatment. The phrase 'very safe' attributed to the expert is doing a lot of heavy lifting here. The video seems to be suggesting that because mainstream Irish media and hospital clinicians are on board, any safety concerns about GLP-1 receptor agonists are overblown. It's also implicitly gesturing toward alternative access routes, which the hashtag pattern around shortages tends to do. The caption cuts off mid-sentence, which is a format commonly used to drive profile clicks and views. Without the full transcript we can't confirm the exact claims, but the framing is familiar enough to work with.

What does the science actually show?

Semaglutide has a reasonably solid safety record in the context of clinical trials. The SUSTAIN and STEP trial series, published in the New England Journal of Medicine between 2018 and 2021, consistently showed that 1mg weekly semaglutide produced meaningful HbA1c reductions in type 2 diabetes, and that 2.4mg weekly (the Wegovy dose) produced around 14.9% mean body weight reduction over 68 weeks in people with obesity but without diabetes (Wilding et al., 2021, NEJM). Gastrointestinal side effects, primarily nausea and vomiting, affected roughly 44% of participants in the STEP 1 trial. More serious but rarer signals include pancreatitis risk and thyroid C-cell tumour concerns observed in rodent models, though the human relevance of the latter remains genuinely uncertain. 'Very safe' is a phrase that requires a lot of context. Safe compared to what, in whom, at what dose, over what duration. The trials were 68 weeks. We don't have multi-decade real-world data yet.

Where does the social media noise diverge from clinical reality?

The Ozempic shortage in Ireland and across Europe is real. The European Medicines Agency confirmed supply disruptions for semaglutide products in 2022 and 2023, driven largely by demand that outpaced manufacturing capacity. What social media often skips is why the shortage matters clinically. Patients with type 2 diabetes were the ones most affected first, because Ozempic is licensed for diabetes management in Ireland, not obesity. Wegovy, the obesity-licensed formulation, had a separate and delayed rollout. When creators conflate the two products and their patient populations, it creates confusion about who actually has a medical priority claim on the drug. The safety framing is also flattened on TikTok. Citing an unnamed hospital expert without specifying their specialty, the patient population they treat, or any conflict of interest disclosures is not the same as clinical consensus. RTE covering something is journalism, not a clinical endorsement. These distinctions matter when people are making decisions about accessing medications outside standard prescribing channels.

What should you actually know?

Semaglutide is a legitimate, well-studied medication with real clinical benefits for specific patient populations. The evidence base is genuinely stronger than for most weight management interventions that came before it. But 'very safe' is a phrase that demands precision. The STEP trials excluded people with a history of pancreatitis, active gallbladder disease, and certain thyroid conditions. Real-world populations are messier. Post-marketing surveillance through systems like the FDA's FAERS database has flagged reports of ileus, aspiration during procedures, and worsening of diabetic retinopathy, though causality is not confirmed for all signals. In Ireland, the HPRA regulates semaglutide and its supply. Anyone sourcing it outside a registered prescriber and pharmacy is taking on risks that no TikTok video, however well-intentioned, can quantify for them. If you are considering GLP-1 therapy, the conversation belongs with a clinician who knows your full history, not a comment section.